Angina Pectoris
Introduction
Section titled “Introduction”Angina pectoris, commonly referred to as angina, is a type of chest pain or discomfort caused by reduced blood flow to the heart muscle. It is not a disease itself, but rather a symptom of an underlying heart condition, most frequently coronary artery disease (CAD).[1]This condition arises when the heart muscle does not receive enough oxygen-rich blood, typically during physical exertion or emotional stress.
Biological Basis
Section titled “Biological Basis”The primary biological basis for angina pectoris is myocardial ischemia, a state where the heart muscle experiences an imbalance between oxygen supply and demand. This imbalance is most often due to atherosclerosis, a process where fatty plaque builds up in the coronary arteries, narrowing them and restricting blood flow to the myocardium. When the heart’s demand for oxygen increases (e.g., during exercise), these narrowed arteries cannot supply sufficient blood, leading to oxygen deprivation and the characteristic pain of angina. Genetic factors play a significant role in an individual’s susceptibility to coronary artery disease and, consequently, to angina. Genome-wide association studies have identified common variants associated with CAD, such as those found on chromosome 9p21.3, includingrs7044859 , rs1292136 , rs7865618 , and rs1333049 .[2] Other genetic variants influencing cardiac structure and function, or coagulation factors like those in F12, KNG1, and HRG, can also contribute to the overall risk of cardiovascular conditions that manifest as angina.[3]
Clinical Relevance
Section titled “Clinical Relevance”Clinically, angina presents as a squeezing, pressure, heaviness, tightness, or pain in the chest, often radiating to the left arm, neck, jaw, back, or shoulder. It is a critical warning sign that the heart muscle is not receiving adequate blood supply and can indicate a heightened risk for more severe cardiovascular events, including acute myocardial infarction (heart attack) or ischemic stroke.[4]Recognizing and managing angina is crucial for preventing progression of coronary artery disease and improving patient outcomes.
Social Importance
Section titled “Social Importance”Angina pectoris and its underlying cause, coronary heart disease, represent a major public health challenge globally. Coronary heart disease is a leading cause of mortality.[4]and angina significantly impacts the quality of life for millions, leading to limitations in physical activity, anxiety, and a substantial burden on healthcare systems. Understanding the genetic and environmental factors contributing to angina is vital for developing effective prevention strategies, early diagnostic tools, and personalized treatment approaches, ultimately aiming to reduce the prevalence and impact of cardiovascular disease.
Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”Research into complex traits like angina pectoris often faces inherent methodological and statistical challenges that influence the interpretation and generalizability of findings. Studies may have insufficient statistical power to detect genetic effects that contribute only modestly to phenotypic variation, especially when considering the extensive multiple testing inherent in genome-wide association studies (GWAS).[5]While some studies demonstrate high power for larger effect sizes, the ability to identify more subtle genetic influences can be limited by sample size and the scope of genetic variation covered by genotyping platforms.[5] This constraint means that potentially relevant genetic factors explaining smaller proportions of the trait’s variability might be missed, leading to an incomplete understanding of its genetic architecture.
Furthermore, the robustness of identified associations necessitates rigorous validation, often requiring replication in independent cohorts to confirm findings and prevent the reporting of false positives.[6] The absence of such replication can inflate perceived effect sizes or lead to associations that do not hold true across different populations or study designs.[5] Without external validation, the clinical utility of identified genetic markers for risk prediction or therapeutic targeting remains uncertain, underscoring the need for broader collaborative efforts and standardized methodologies to enhance reproducibility.
Phenotypic Definition and Inconsistencies
Section titled “Phenotypic Definition and Inconsistencies”The precise definition and of complex cardiac phenotypes, which underpin conditions like angina pectoris, present significant challenges that can affect study outcomes. Reliance on diagnostic codes, while practical for large-scale biobank research, introduces a risk of misclassification for study outcomes.[6] Such misclassification, even with curated outcome sets, can weaken the observed associations between genetic variants and the phenotype, potentially obscuring true biological relationships.
Additionally, the use of uniform thresholds for physiological measurements, such as left ventricular size and function, without accounting for sex-specific differences, can lead to subtle inaccuracies in participant stratification.[6]Although statistical models may partially adjust for sex, the initial inclusion of individuals whose measurements fall just outside sex-specific normal ranges when using generalized thresholds can introduce bias. These inconsistencies can impact the homogeneity of study groups and the accuracy of identifying genetic risk factors for angina pectoris and related cardiac conditions.
Generalizability and Environmental Confounders
Section titled “Generalizability and Environmental Confounders”Genetic insights derived from specific cohorts may not be broadly generalizable across diverse populations, limiting their applicability to the wider population. Many genetic studies, particularly GWAS, often restrict participants to a subset of individuals from similar ancestral backgrounds (e.g., European ancestry) to mitigate inflation due to population substructure.[6]This approach, while statistically sound for controlling confounding, can result in findings that are less relevant or even inaccurate for individuals of other ancestries, hindering the development of equitable precision medicine strategies for angina pectoris.
Moreover, the interplay between genetic predisposition and environmental factors is crucial for understanding complex traits, yet this aspect is frequently unexplored. Genetic variants can influence phenotypes in a context-specific manner, with their effects modulated by various environmental influences such as dietary habits or lifestyle factors.[5]The omission of comprehensive investigations into gene-environment interactions leaves a significant gap in knowledge, as it fails to account for how environmental exposures might modify genetic risk for angina pectoris, thus contributing to the ‘missing heritability’ phenomenon and limiting a holistic understanding of the disease.
Variants
Section titled “Variants”Genetic variations play a crucial role in an individual’s susceptibility to angina pectoris, a condition characterized by chest pain due to reduced blood flow to the heart. Several genes and their specific variants influence various aspects of cardiovascular health, including lipid metabolism, vascular function, and inflammation. For instance, variants within the_LPA_ gene, such as rs10455872 , rs55730499 , and rs140570886 , are significant given _LPA_’s role in producing lipoprotein(a), a lipid particle structurally similar to LDL cholesterol but with an added protein called apolipoprotein(a). Elevated levels of lipoprotein(a) are a recognized risk factor for atherosclerosis, contributing to plaque buildup in arteries that can restrict blood flow and lead to angina. Similarly, variants in the_LPA - PLG_ locus, including rs56393506 and rs10806735 , may affect the interaction between lipoprotein(a) and plasminogen (_PLG_), potentially interfering with fibrinolysis, the body’s natural process for dissolving blood clots, thereby increasing thrombotic risk and aggravating angina.
Other critical genes involved in lipid processing and inflammation include _CELSR2_ and the _APOE - APOC1_ cluster. The _CELSR2_ gene, along with _PSRC1_ and _SORT1_, forms a locus associated with plasma lipid levels. Variants like rs12740374 , rs660240 , and rs629301 within _CELSR2_, and rs646776 in the _CELSR2 - PSRC1_region, have been linked to variations in low-density lipoprotein (LDL) cholesterol levels, which are primary drivers of atherosclerosis.[7] Specifically, _CELSR2_has been associated with lipoprotein-associated phospholipase A2 (Lp-PLA2) activity.[8] an enzyme involved in inflammation within arterial plaques. The _APOE - APOC1_ gene cluster is central to lipid transport and metabolism, with variants like rs1065853 potentially influencing the composition and function of lipoproteins and their interaction with arterial walls. The _APOE-APOC1_ cluster also shows significant associations with Lp-PLA2 activity, further highlighting its role in inflammatory processes that contribute to angina.[8] Beyond lipid metabolism, genetic variations in genes affecting cell proliferation and vascular tone contribute to angina risk. The _CDKN2B-AS1_gene, an antisense RNA, is located in a region on chromosome 9p21.3 that is strongly associated with coronary artery disease (CAD), a common underlying cause of angina.[2] Variants such as rs1537371 , rs10757274 , and rs4007642 in this locus are thought to influence the expression of _CDKN2A_ and _CDKN2B_, genes that regulate cell cycle and proliferation, impacting the growth of vascular smooth muscle cells and contributing to plaque formation. Variants in_PHACTR1_ (rs9349379 , rs747206656 ) may affect vascular stability and tone, influencing blood vessel constriction and dilation, which are critical for maintaining adequate blood flow to the heart. Similarly, the _PRMT5P1 - EDNRA_ locus, including variants like rs149299884 , rs10305838 , and rs58721068 , is relevant due to _EDNRA_’s role as an endothelin receptor, mediating the potent vasoconstrictive effects of endothelin, a peptide that can narrow blood vessels and exacerbate angina. The_ALDH2_ gene, with its common variant rs671 , plays a role in metabolizing acetaldehyde, a toxic compound produced from alcohol. Reduced _ALDH2_activity can lead to facial flushing and increased cardiovascular stress. Finally, the_NAA25_ gene, represented by variant rs11066132 , is involved in protein N-alpha-acetylation, a fundamental cellular process that impacts protein stability and function, with broad implications for cellular health and potential indirect effects on cardiovascular function.
Key Variants
Section titled “Key Variants”Phenotypic Heterogeneity and Associated Factors
Section titled “Phenotypic Heterogeneity and Associated Factors”The clinical presentation of cardiovascular conditions, including angina pectoris, is influenced by a diverse array of factors that contribute to inter-individual variation and phenotypic diversity. Research indicates that age, body mass index, current cigarette smoking, and the presence of prevalent cardiovascular disease are significant covariates in analyses of various physiological phenotypes.[9]These factors, alongside conditions such as diabetes, hypertension, and dyslipidemia (indicated by triglycerides, total cholesterol, and the ratio of total cholesterol to high-density lipoprotein cholesterol), can modify the overall cardiovascular risk profile and impact how related conditions manifest.[9]Sex also plays a crucial role in mediating cardiovascular phenotypes, with studies exploring its potential mediating effects in cardiac morphogenesis and its implications for disease development.[10]Estrogen therapy in women is another factor considered in studies of cardiovascular health, highlighting sex-specific considerations in understanding phenotypic expression and variability.[9]Such heterogeneity necessitates a comprehensive assessment of patient-specific factors when evaluating cardiovascular status.
Objective Physiological and Morphological Assessment
Section titled “Objective Physiological and Morphological Assessment”Objective approaches are integral to evaluating cardiovascular health and identifying underlying pathologies. Systolic and diastolic blood pressure are fundamental physiological measures that provide insights into the hemodynamic state and are consistently assessed in clinical and research settings.[9]These objective metrics contribute to characterizing cardiovascular phenotypes and are often considered in conjunction with other clinical parameters.
Furthermore, advanced diagnostic tools like ECHO-derived left ventricular (LV) measurements offer detailed insights into cardiac morphology and function, which are crucial for understanding the structural basis of cardiovascular disease and its progression, including conditions that may lead to symptoms like angina.[10]Beyond structural assessments, hematological phenotypes such as platelet aggregation (measured via ADP-, collagen-, and Epi-induced methods) provide objective data on hemostatic function, reflecting aspects of blood coagulability that are relevant to cardiovascular health.[9]
Clinical Relevance and Risk Indicators
Section titled “Clinical Relevance and Risk Indicators”The factors and measurements discussed hold significant diagnostic value and serve as crucial prognostic indicators in the broader context of cardiovascular disease. The presence of prevalent cardiovascular disease, coupled with risk factors such as hypertension, diabetes, dyslipidemia, and a history of smoking, are strong clinical correlations that guide differential diagnosis and risk stratification.[9]These indicators are essential for identifying individuals at higher risk for ischemic events and for evaluating the severity and potential progression of underlying cardiovascular pathology.
Monitoring these factors, including systolic and diastolic blood pressure, and assessing cardiac morphology through methods like echocardiography, helps clinicians identify “red flags” and establish a comprehensive clinical picture.[10]This integrated approach, considering both patient-reported experiences and objective measurements, is vital for the accurate diagnosis and management of cardiovascular conditions, including the various clinical phenotypes of angina pectoris.
Causes of Angina Pectoris
Section titled “Causes of Angina Pectoris”Angina pectoris, a manifestation of myocardial ischemia, arises from a complex interplay of genetic predispositions, environmental exposures, and other physiological factors that primarily lead to coronary artery disease (CAD). The underlying cause is typically atherosclerosis, a condition characterized by the build-up of plaque in the coronary arteries, restricting blood flow to the heart muscle.
Genetic Predisposition
Section titled “Genetic Predisposition”Genetic factors play a significant role in an individual’s susceptibility to angina and its underlying cause, coronary artery disease. Studies of twins have demonstrated a clear genetic susceptibility to coronary heart disease, indicating an inherited component to risk.[11] This predisposition is often polygenic, involving multiple genetic variants that collectively increase risk, as revealed by genome-wide association studies (GWAS) that analyze numerous genetic markers across the human genome.[12] Such studies aim to identify specific inherited variants that contribute to the development of CAD.
Furthermore, specific gene polymorphisms have been linked to increased risk for premature CAD and its complications. For instance, a common X-linked polymorphism, the -1332 G/A variant in the angiotensin II type 2-receptor (AGTR2) gene, has been associated with premature myocardial infarction and stenotic atherosclerosis requiring revascularization.[13]Familial studies, such as genome-wide linkage analyses in families affected by premature coronary artery disease, further underscore the importance of inherited factors in determining an individual’s risk trajectory for developing conditions that lead to angina.[14]
Environmental and Lifestyle Factors
Section titled “Environmental and Lifestyle Factors”Beyond genetics, a substantial portion of angina risk is attributable to environmental and lifestyle choices that promote atherosclerosis. Potentially modifiable risk factors have been extensively identified globally, demonstrating a clear link between daily habits and cardiovascular health.[15]These include dietary patterns high in saturated fats, physical inactivity, and exposure to tobacco smoke, all of which contribute to plaque formation and arterial narrowing. The INTERHEART study, which investigated modifiable risk factors across 52 countries, highlighted the significant impact of these lifestyle elements on the occurrence of myocardial infarction, a condition often heralded by angina.[16]Socioeconomic factors and geographic influences also contribute to the burden of angina by shaping access to healthy diets, opportunities for physical activity, and exposure to environmental stressors. These broader societal determinants can exacerbate individual risk, particularly when combined with other predisposing factors. Collectively, these environmental inputs contribute to systemic inflammation, dyslipidemia, and endothelial dysfunction, accelerating the atherosclerotic process that ultimately restricts coronary blood flow and triggers anginal symptoms.
Complex Interplay of Genetics and Environment
Section titled “Complex Interplay of Genetics and Environment”Angina pectoris is often the result of intricate gene-environment interactions, where an individual’s genetic susceptibility is significantly modulated by their environmental exposures and lifestyle choices. For example, while certain genetic variants might predispose an individual to higher cholesterol levels or increased inflammatory responses, the actual clinical manifestation of atherosclerosis and angina is often accelerated or mitigated by dietary habits, exercise routines, and smoking status. A person with a polygenic risk for CAD might develop severe angina at an earlier age if they also adhere to an unhealthy lifestyle, whereas a similar genetic profile might lead to less severe or later-onset disease in a healthier environment.
This interaction means that genetic predispositions do not act in isolation but rather influence how an individual responds to environmental triggers. The cumulative effect of multiple genetic variants interacting with chronic environmental exposures, such as prolonged exposure to pollutants or sustained psychological stress, can overwhelm the cardiovascular system’s compensatory mechanisms. Understanding these complex interactions is crucial for identifying individuals at highest risk and for developing personalized prevention strategies that address both inherited vulnerabilities and modifiable external factors.
Other Contributing Factors
Section titled “Other Contributing Factors”Several other factors modify the risk and presentation of angina pectoris, often compounding the effects of genetic and environmental influences. Age is a significant non-modifiable risk factor, with the incidence of coronary artery disease and subsequent angina generally increasing with advancing age due to cumulative arterial damage and reduced vascular elasticity. While premature coronary artery disease can occur due to strong genetic or severe environmental factors, the overall burden of angina is higher in older populations.[14]Co-morbidities also play a critical role, as conditions like hypertension, diabetes mellitus, and hyperlipidemia are established risk factors for atherosclerosis and, consequently, angina. These conditions often have their own genetic and environmental underpinnings, creating a synergistic effect that accelerates vascular damage. For example, poorly controlled diabetes can hasten endothelial dysfunction and plaque formation, while chronic hypertension places increased stress on arterial walls. The presence of these co-existing diseases significantly elevates the risk of developing and experiencing more severe or frequent angina.
Biological Background of Angina Pectoris
Section titled “Biological Background of Angina Pectoris”Angina pectoris, commonly known as angina, is a symptom characterized by chest pain or discomfort, typically resulting from myocardial ischemia. This condition arises when the heart muscle does not receive enough oxygen-rich blood, most often due to underlying coronary artery disease (CAD). CAD involves the narrowing or blockage of the coronary arteries, which supply blood to the heart, primarily through a process called atherosclerosis. Understanding the biological underpinnings of angina involves examining the complex interplay of cardiovascular pathophysiology, cellular signaling, genetic predispositions, and metabolic pathways that contribute to the development and progression of atherosclerosis and subsequent myocardial ischemia.
Pathophysiology of Coronary Artery Disease and Myocardial Ischemia
Section titled “Pathophysiology of Coronary Artery Disease and Myocardial Ischemia”Angina pectoris is a direct manifestation of myocardial ischemia, a state where the oxygen supply to the heart muscle is insufficient to meet its metabolic demands. This imbalance is predominantly caused by coronary artery disease, a condition characterized by the accumulation of atherosclerotic plaques within the walls of the coronary arteries, which are the primary vessels supplying blood to the heart. These plaques progressively narrow the arterial lumen, restricting blood flow and thus oxygen delivery to the myocardium, particularly during periods of increased demand such as physical exertion or emotional stress.[14]The reduced blood flow, or ischemia, triggers the chest pain associated with angina. Over time, these plaques can become unstable, rupture, and lead to the formation of thrombi, potentially causing acute coronary syndromes like myocardial infarction.[14]The development of atherosclerosis is a complex pathophysiological process involving the arterial wall at a tissue and organ level. It begins with endothelial dysfunction, followed by the infiltration of lipids, particularly low-density lipoproteins (LDL), into the arterial intima. This triggers an inflammatory response, attracting monocytes that differentiate into macrophages, engulf lipids to become foam cells, and contribute to plaque formation. Vascular smooth muscle cells (VSMCs) also play a critical role, migrating from the media to the intima, proliferating, and producing extracellular matrix components, which contribute to the fibrous cap of the plaque.[17] The progression of these plaques ultimately leads to the significant narrowing of coronary arteries, creating the conditions for anginal symptoms.
Cellular and Molecular Mechanisms of Atherosclerosis
Section titled “Cellular and Molecular Mechanisms of Atherosclerosis”At the cellular and molecular level, atherosclerosis involves a cascade of events within the arterial wall. Vascular smooth muscle cells (VSMCs) are central to this process, and their phenotype can significantly influence plaque stability and progression. For instance, specific genetic variations on chromosome 9p21 have been functionally analyzed in VSMCs and are associated with coronary artery disease, highlighting the role of these cells in the disease.[18] Another key molecule, ADAMTS7, an enzyme involved in extracellular matrix remodeling, influences VSMC migration, a process affected by coronary artery disease-associated variants.[19] The abnormal migration and proliferation of VSMCs contribute to the thickening of the arterial wall and the formation of the fibrous cap of atherosclerotic plaques.
Beyond structural changes, cellular functions like calcification also play a significant role in atherosclerotic progression. Histone deacetylase 9 (HDAC9) is implicated in atherosclerotic aortic calcification and impacts vascular smooth muscle cell phenotype.[20] HDAC9 belongs to a family of enzymes that regulate gene expression by modifying chromatin structure through histone acetylation, influencing cellular processes crucial for vascular health.[21]Additionally, Notch signaling has been identified as a pathway involved in cardiovascular disease and vascular calcification, further demonstrating the intricate regulatory networks at play in the arterial wall.[22]These molecular mechanisms contribute to the chronic inflammation and structural changes that define atherosclerosis.
Genetic and Epigenetic Influences on Vascular Health
Section titled “Genetic and Epigenetic Influences on Vascular Health”Genetic mechanisms significantly contribute to an individual’s susceptibility to coronary artery disease and, consequently, angina. Genome-wide association studies (GWAS) have identified numerous genetic loci associated with coronary artery disease risk.[23]For example, variations on chromosome 9p21 are strongly linked to CAD, and their functional impact on vascular smooth muscle cells has been investigated, revealing how specific genetic changes can alter cellular behavior relevant to atherosclerosis.[18] Another gene, ADAMTS7, is known to be involved in vascular smooth muscle cell migration, and certain variants affect this process, contributing to coronary artery disease susceptibility.[19]These genetic predispositions highlight the inherited component of vascular disease.
Epigenetic modifications, such as histone acetylation, also play a crucial role in regulating gene expression patterns relevant to vascular health. Histone deacetylases (HDACs), like HDAC9, are enzymes that remove acetyl groups from histones, thereby altering chromatin structure and influencing gene transcription.[21] The involvement of HDAC9in atherosclerotic aortic calcification and its effect on vascular smooth muscle cell phenotype suggest that epigenetic regulation can profoundly impact the development and progression of atherosclerosis.[20]These regulatory networks, acting on top of the genetic code, modulate the expression of genes involved in inflammation, lipid metabolism, and cellular differentiation, contributing to the complex etiology of coronary artery disease.
Metabolic and Inflammatory Pathways in Angina
Section titled “Metabolic and Inflammatory Pathways in Angina”Metabolic processes and inflammatory responses are intricately linked to the development of atherosclerosis and the presentation of angina. Lipids, particularly circulating sphingolipids, have been identified as genetic determinants influencing coronary heart disease risk.[24]Dysregulation of lipid metabolism, including the ratio of arachidonic acid to linoleic acid, is associated with inflammation and coronary artery disease, suggesting a critical role for fatty acid desaturase (FADS) genotypes in this pathway.[25]Sphingolipids, which include ceramides, are also implicated in insulin resistance and metabolic disease, further connecting metabolic disruptions to cardiovascular pathology.[26]Inflammation is a hallmark of atherosclerosis, driven by complex signaling pathways involving various immune regulators. The genetic architecture of the adaptive immune system identifies key immune regulators that may contribute to the inflammatory environment within atherosclerotic plaques.[27]For instance, ceramide, a type of sphingolipid, is known to trigger cardiomyocyte apoptosis (programmed cell death) during ischemia and reperfusion, a process highly relevant to the damage incurred during myocardial ischemia.[28] These interconnected metabolic and inflammatory pathways contribute to homeostatic disruptions in the vasculature, exacerbating plaque formation and increasing the risk of anginal episodes.
Molecular Signaling in Vascular and Myocardial Function
Section titled “Molecular Signaling in Vascular and Myocardial Function”Angina pectoris, a manifestation of myocardial ischemia, involves complex molecular signaling pathways that regulate vascular tone, cardiac remodeling, and inflammatory responses. The Renin-Angiotensin-Aldosterone System (RAAS) plays a critical role, where variants in genes likeACE and AGTexert epistatic effects on left ventricular mass in hypertensive patients, influencing cardiac hypertrophy.[29] Angiotensin II, a key RAAS effector, has been shown to increase phosphodiesterase 5A (PDE5A) expression in vascular smooth muscle cells, thereby antagonizing cGMP signaling and contributing to vasoconstriction.[30] Furthermore, aldosterone specifically activates cardiomyocyte mineralocorticoid receptors, impacting cardiac function and potentially contributing to pathological remodeling.[31]Beyond RAAS, other crucial signaling cascades like the Mitogen-Activated Protein Kinase (MAPK) pathway are activated in response to various stimuli, including age and acute exercise, influencing cellular processes in tissues like skeletal muscle, and by extension, potentially cardiac muscle and vasculature.[5]Under conditions such as high glucose, the JAK2/STAT3 pathway mediatesVEGF upregulation, a process that can be inhibited by PEDF through a mitochondrial ROS pathway, highlighting the interplay between metabolic stress, oxidative stress, and pro-angiogenic signaling.[32]Such intricate signaling crosstalk and feedback loops are fundamental to maintaining cardiovascular homeostasis, but their dysregulation contributes significantly to the pathophysiology underlying angina.
Epigenetic and Transcriptional Regulation of Cardiovascular Health
Section titled “Epigenetic and Transcriptional Regulation of Cardiovascular Health”Gene regulation and epigenetic modifications are central to shaping cellular phenotypes and responses in the cardiovascular system, contributing to the development of conditions like atherosclerosis and myocardial hypertrophy. Histone deacetylases (HDACs) are key regulatory enzymes, withHDAC9specifically implicated in atherosclerotic aortic calcification and affecting vascular smooth muscle cell phenotype.[20] HDAC5 and HDAC9also play redundant roles in heart development and govern the heart’s responsiveness to various stress signals, demonstrating their critical function in both normal physiology and disease adaptation.[33] The broader process of histone acetylation, regulated by HDACs, directly impacts chromatin structure and gene transcription, influencing the expression of numerous genes vital for vascular and cardiac cell function.[21]Dysregulation of these epigenetic mechanisms can lead to aberrant gene expression patterns, promoting pathological changes such as vascular smooth muscle cell calcification and adverse myocardial remodeling, which are core mechanisms in the progression of cardiovascular disease and the exacerbation of angina. TheNppa-Nppbcluster locus, for instance, has a defined structure and function during heart development and disease, underscoring the importance of precise genetic regulation in maintaining cardiac health.[34]
Metabolic Reprogramming and Energy Metabolism Dysregulation
Section titled “Metabolic Reprogramming and Energy Metabolism Dysregulation”The heart’s continuous high energy demand necessitates robust and adaptable metabolic pathways, and their dysregulation is a central mechanism in angina pectoris, often described as the “failing heart—an engine out of fuel”.[35]Metabolite profiling has been instrumental in identifying pathways associated with metabolic risk in humans, providing insights into the metabolic shifts that precede or accompany cardiovascular disease.[36]For example, tryptophan metabolism can produce uremic toxins that activate the aryl hydrocarbon receptor, a novel mechanism linking chronic kidney disease and its cardiovascular complications.[37]This metabolic flux control is critical; imbalances in energy metabolism, including biosynthesis and catabolism, can lead to inadequate ATP production or accumulation of toxic intermediates, impairing myocardial contractility and endothelial function. Kynurenine, a product of tryptophan metabolism, acts as an endothelium-derived relaxing factor produced during inflammation, illustrating how metabolic intermediates can have direct regulatory effects on vascular tone.[38]Therefore, understanding and targeting specific metabolic pathways and their regulatory mechanisms offers significant therapeutic potential for addressing myocardial ischemia and its symptomatic manifestation, angina.
Proteostasis and Cellular Stress Responses
Section titled “Proteostasis and Cellular Stress Responses”Maintaining protein homeostasis, or proteostasis, is crucial for cellular health, and its disruption, particularly under stress, contributes significantly to cardiovascular disease pathogenesis. The Ubiquitin-Proteasome System (UPS) is a primary cellular mechanism for protein degradation and quality control, and its dysregulation has been strongly implicated in human carotid atherosclerosis.[39]Increased activity of the UPS in patients with symptomatic carotid disease is associated with enhanced inflammation and may contribute to the destabilization of atherosclerotic plaques, highlighting its role in disease progression.[40] In parallel, endoplasmic reticulum (ER) stress, which occurs when misfolded proteins accumulate in the ER, triggers specific gene expression programs and genetic variations in response to this cellular perturbation.[41]The interplay between ER stress and UPS dysfunction creates a feedback loop where impaired protein degradation exacerbates ER stress, and vice versa, contributing to cellular damage and inflammation in the vasculature and myocardium. Therapeutic interventions, such as rosiglitazone treatment, have shown effects on UPS activity in the context of symptomatic carotid disease, suggesting that modulating proteostasis pathways can be a viable strategy for managing cardiovascular pathology.[40]
Systems-Level Integration and Disease Mechanisms
Section titled “Systems-Level Integration and Disease Mechanisms”Cardiovascular disease involves a complex network of interacting pathways and hierarchical regulation, where pathway crosstalk and emergent properties dictate disease progression and therapeutic responses. For example, the disruption of theCFTRchloride channel alters the mechanical properties and cAMP-dependent chloride transport of mouse aortic smooth muscle cells, indicating a direct link between ion channel function and vascular mechanics.[42] CFTR expression and chloride channel activity are also characterized in human endothelia, underscoring its broad relevance to vascular function.[43] Furthermore, NTAK/neuregulin-2 isoforms possess an N-terminal region with inhibitory activity on angiogenesis, illustrating how specific molecular components can regulate complex physiological processes like new blood vessel formation, which is vital in ischemic conditions.[44]Notch signaling is another critical pathway involved in cardiovascular disease and calcification, demonstrating its widespread impact on vascular health.[22]Understanding these network interactions and how pathway dysregulation leads to compensatory mechanisms, such as those seen in left ventricular hypertrophy, is crucial for identifying novel therapeutic targets and developing integrated clinical and molecular biosignatures for reclassifying cardiovascular risk.[45]
Clinical Relevance of Angina Pectoris
Section titled “Clinical Relevance of Angina Pectoris”Angina pectoris, a symptom primarily indicating myocardial ischemia, holds significant clinical relevance in the diagnosis, risk stratification, and management of cardiovascular disease. Understanding its underlying mechanisms and associated factors is crucial for improving patient outcomes.
Risk Assessment and Personalized Medicine
Section titled “Risk Assessment and Personalized Medicine”Angina pectoris serves as a critical indicator for initiating comprehensive cardiovascular risk assessment and guiding personalized medicine approaches. Traditional risk factors, combined with advanced diagnostic tools, are employed to identify individuals at high risk for major adverse cardiovascular events (MACE) and disease progression. For instance, the Framingham ATP-III risk score, which incorporates factors like smoking and diabetes status, is routinely used in risk stratification. The inclusion of novel biomarkers, such as serum ceruloplasmin (Cp), has been explored to enhance predictive models for MACE risk, demonstrating improved model performance as evaluated by net reclassification improvement (NRI) and area under the receiver operating characteristic curve (AUC) analyses.[46] Such refined risk models facilitate early intervention strategies and tailored preventative measures, moving towards more personalized patient care by precisely identifying individuals who could benefit most from targeted therapies.
Prognostic Indicators and Disease Management
Section titled “Prognostic Indicators and Disease Management”The presence and characteristics of angina pectoris are pivotal in assessing prognosis and guiding long-term disease management strategies. The severity and frequency of anginal symptoms can reflect the extent of coronary artery disease (CAD) and predict future cardiovascular events. Monitoring changes in anginal patterns, whether stable or unstable, is essential for evaluating disease progression and the effectiveness of ongoing treatments. Furthermore, genetic variants identified through genome-wide association studies (GWAS) for cardiovascular disease outcomes provide insights into individual susceptibility and potential response to therapies.[47]These genetic insights, alongside biomarker monitoring, can inform treatment selection, such as anti-ischemic medications or revascularization procedures, and help tailor monitoring strategies to mitigate the long-term implications of myocardial ischemia and reduce the likelihood of complications like myocardial infarction or heart failure.
Genetic Susceptibility and Comorbid Associations
Section titled “Genetic Susceptibility and Comorbid Associations”Angina pectoris is frequently associated with a spectrum of comorbidities and overlapping phenotypes, underscoring the systemic nature of cardiovascular disease. Conditions like diabetes mellitus, hypertension, dyslipidemia (low- and high-density lipoprotein, triglycerides), and inflammation (e.g., elevated C-reactive protein and ceruloplasmin) are commonly observed in patients with angina.[48]Genome-wide association studies have explored genetic variants influencing these associated biomarker traits, including those related to inflammation/oxidative stress (e.g., CD40 Ligand, Interleukin-6, Myeloperoxidase) and natriuretic peptides (N-terminal pro-atrial natriuretic peptide, B-type natriuretic peptide).[48]Understanding these genetic predispositions and biomarker profiles helps to identify patients with complex syndromic presentations, allowing for integrated management plans that address not only the angina itself but also the broader cardiovascular risk landscape and related systemic conditions.
Frequently Asked Questions About Angina Pectoris
Section titled “Frequently Asked Questions About Angina Pectoris”These questions address the most important and specific aspects of angina pectoris based on current genetic research.
1. My family has a history of heart issues. Am I more likely to get angina?
Section titled “1. My family has a history of heart issues. Am I more likely to get angina?”Yes, absolutely. Your genetic background significantly influences your risk for coronary artery disease (CAD), which is the main cause of angina. Studies have identified specific genetic variants, like those on chromosome 9p21.3 (e.g.,rs1333049 ), that increase susceptibility. While genetics play a role, it doesn’t mean it’s inevitable; lifestyle choices can still make a big difference.
2. My friend is healthy, but I get chest pain sometimes. Why the difference?
Section titled “2. My friend is healthy, but I get chest pain sometimes. Why the difference?”Even with similar healthy lifestyles, genetic differences can explain why you experience chest pain and your friend doesn’t. Some individuals have genetic predispositions that make them more susceptible to plaque buildup in arteries, even without obvious risk factors. Variants influencing cardiac function or coagulation factors likeF12 or KNG1 can contribute to this hidden risk, leading to angina symptoms.
3. Why does my chest hurt when I exercise, even a little?
Section titled “3. Why does my chest hurt when I exercise, even a little?”This is a classic sign of angina, indicating your heart muscle isn’t getting enough oxygen-rich blood during exertion. Genetically, you might be more prone to atherosclerosis, where fatty plaque builds up and narrows your coronary arteries. When your heart works harder during exercise, these narrowed arteries can’t supply enough blood, leading to the characteristic pain.
4. Can stress actually trigger my chest pain, or is it just my mind?
Section titled “4. Can stress actually trigger my chest pain, or is it just my mind?”Stress can absolutely trigger chest pain. Angina is caused by an imbalance between oxygen supply and demand in the heart, and emotional stress increases your heart’s demand for oxygen. If you have underlying coronary artery disease, which can have a genetic component, your narrowed arteries may struggle to meet this increased demand, leading to real physical pain.
5. If my family has heart issues, can I still prevent angina?
Section titled “5. If my family has heart issues, can I still prevent angina?”Yes, you absolutely can take steps to prevent angina, even with a strong family history. While genetic factors significantly increase your susceptibility to conditions like coronary artery disease, they don’t dictate your fate entirely. Lifestyle choices like a healthy diet, regular exercise, and managing stress can help mitigate your genetic risk by reducing plaque buildup and improving heart health.
6. Could a DNA test tell me my personal angina risk?
Section titled “6. Could a DNA test tell me my personal angina risk?”Yes, a DNA test could provide insights into your genetic predisposition for conditions like coronary artery disease, which causes angina. These tests can identify specific genetic variants, such as those on chromosome 9p21.3, known to be associated with increased risk. However, remember that genetic risk is only one piece of the puzzle, and environmental factors also play a huge role.
7. Does my family’s ancestry affect my angina risk?
Section titled “7. Does my family’s ancestry affect my angina risk?”Yes, your ancestry can influence your angina risk. Many genetic studies, especially genome-wide association studies, have historically focused on populations of European ancestry. This means that genetic findings might not be as relevant or accurate for individuals from other ancestral backgrounds, as different populations may have unique genetic risk factors or varying frequencies of common variants.
8. Why do I get chest pain sometimes, even when I’m not exerting myself?
Section titled “8. Why do I get chest pain sometimes, even when I’m not exerting myself?”While angina is typically triggered by physical exertion or emotional stress, it can sometimes occur with less obvious triggers, especially if your underlying coronary artery disease is more severe. This pain still indicates that your heart muscle isn’t getting enough oxygen. Genetic factors can contribute to the severity of atherosclerosis, making your arteries more prone to restricting blood flow even at rest.
9. If I get angina, does it mean a heart attack is next for me?
Section titled “9. If I get angina, does it mean a heart attack is next for me?”Angina is a critical warning sign that your heart muscle isn’t receiving adequate blood supply, indicating a heightened risk for more severe cardiovascular events like a heart attack or stroke. It doesn’t mean a heart attack isnextor inevitable, but it signifies the need for immediate medical attention and management to prevent progression of coronary artery disease and improve your outcomes.
10. Does my diet matter for angina if my genes are against me?
Section titled “10. Does my diet matter for angina if my genes are against me?”Absolutely, your diet matters significantly, even if you have a genetic predisposition to angina. Genetic variants influence your susceptibility, but environmental factors like diet and lifestyle profoundly modulate how those genes express themselves. A healthy diet can help manage risk factors like high cholesterol and blood pressure, slowing the progression of atherosclerosis and reducing your overall angina risk.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
Section titled “References”[1] Dichgans, M. “Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants.”Stroke, 2013.
[2] Samani NJ. “Genomewide association analysis of coronary artery disease.”N Engl J Med.
[3] Houlihan, LM. “Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time.” Am J Hum Genet, 2010.
[4] Centers for Disease Control and Prevention (CDC). “Mortality from coronary heart disease and acute myocardial infarction—United Wkly. Rep. 50, 90–93.” 2001.
[5] Vasan, R. S., et al. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Med Genet, vol. 8, 2007, p. 64.
[6] Vukadinovic, Milan, et al. “Deep learning-enabled analysis of medical images identifies cardiac sphericity as an early marker of cardiomyopathy and related outcomes.”Med, 2023.
[7] Ferrucci, L. et al. “Common variation in the beta-carotene 15,15’-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study.” Am J Hum Genet, vol. 84, no. 2, 2009, pp. 123-133.
[8] Grallert, H. et al. “Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies.”Eur Heart J, vol. 33, no. 1, 2012, pp. 23-33.
[9] Yang, Q. et al. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Med Genet, 2007.
[10] Aung, N. et al. “Genome-Wide Analysis of Left Ventricular Image-Derived Phenotypes Identifies Fourteen Loci Associated with Cardiac Morphogenesis and Heart Failure Development.”Circulation, 2019.
[11] Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. “Genetic susceptibility to death from coronary heart disease in a study of twins.”N Engl J Med. 1994; 330:1041–6.
[12] Christensen K, Murray JC. “What genome-wide association studies can do for medicine.” N Engl J Med. 2007; 356:1094–7.
[13] Alfakih K, Brown B, Lawrance RA, et al. “Effect of a common X-linked angiotensin II type 2-receptor gene polymorphism (-1332 G/A) on the occurrence of premature myocardial infarction and stenotic atherosclerosis requiring revascularization.”Atherosclerosis.
[14] Samani, N.J. et al. “Genomewide association analysis of coronary artery disease.”N Engl J Med, vol. 357, no. 5, 2007, pp. 443-453.
[15] Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. “Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.”Lancet. 2006; 367:1747–57.
[16] Yusuf S, Hawken S, Ounpuu S, et al. “Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.” Lancet. 2004; 364:937–52.
[17] Aherrahrou, Redouane, et al. “Genetic Regulation of Atherosclerosis-Relevant Phenotypes in Human Vascular Smooth Muscle Cells.”Circulation Research, 2020.
[18] Motterle, Alisa, et al. “Functional Analyses of Coronary Artery Disease Associated Variation on Chromosome 9p21 in Vascular Smooth Muscle Cells.”Human Molecular Genetics, vol. 21, no. 18, 2012, pp. 4021–4029.
[19] Pu, Xiaohong, et al. “ADAMTS7Cleavage and Vascular Smooth Muscle Cell Migration Is Affected by a Coronary-Artery-Disease-Associated Variant.”American Journal of Human Genetics, vol. 92, no. 3, 2013, pp. 366–374.
[20] Malhotra, R., et al. “HDAC9is Implicated in Atherosclerotic Aortic Calcification and Affects Vascular Smooth Muscle Cell Phenotype.”Nature Genetics, 2019.
[21] Grunstein, M. “Histone acetylation in chromatin structure and transcription.” Nature, vol. 389, 1997, pp. 349–52.
[22] Rusanescu, G., et al. “Notch Signaling in Cardiovascular Disease and Calcification.”Current Cardiology Reviews, vol. 4, no. 2, 2008, pp. 148–156.
[23] Erdmann, Jeanette, et al. “New Susceptibility Locus for Coronary Artery Disease on Chromosome 3q22.3.”Nature Genetics, vol. 41, no. 3, 2009, pp. 280–282.
[24] Hicks, Andrew A., et al. “Genetic Determinants of Circulating Sphingolipid Concentrations in European Populations.” PLoS Genetics, vol. 5, no. 9, 2009, e1000672.
[25] Martinelli, Nicola, et al. “FADSGenotypes and Desaturase Activity Estimated by the Ratio of Arachidonic Acid to Linoleic Acid Are Associated with Inflammation and Coronary Artery Disease.”American Journal of Clinical Nutrition, vol. 88, no. 4, 2008, pp. 941–949.
[26] Holland, William L., and Scott A. Summers. “Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from In Vivo Manipulation of Sphingolipid Metabolism.”Endocrine Reviews, vol. 29, no. 4, 2008, pp. 381–402.
[27] Lagou, Vasiliki, et al. “Genetic Architecture of Adaptive Immune System Identifies Key Immune Regulators.” Cell Reports, vol. 25, no. 3, 2018, pp. 798–810.e6.
[28] Bielawska, Anna E., et al. “Ceramide is Involved in Triggering of Cardiomyocyte Apoptosis Induced by Ischemia and Reperfusion.” American Journal of Pathology, vol. 151, no. 5, 1997, pp. 1257-1263.
[29] Ma, J., Guo, L., Fiene, S. J., Anson, B. D., Thomson, J. A., Kamp, T. J., et al. “Epistatic effects of ACE I/D and AGTgene variants on left ventricular mass in hypertensive patients: the HyperGEN study.”J. Hum. Hypertens., vol. 26, 2012.
[30] Kim, D., Aizawa, T., Wei, H., Pi, X., Rybalkin, S. D., Berk, B. C., Yan, C. “Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling.”J Mol Cell Cardiol, vol. 38, 2005, pp. 175-184.
[31] Messaoudi, S., Gravez, B., Tarjus, A., Pelloux, V., Ouvrard-Pascaud, A., Delcayre, C., et al. “Aldosterone-specific activation of cardiomyocyte mineralocorticoid.”
[32] Zheng, Z., Chen, H., Zhao, H., et al. “Inhibition of JAK2/STAT3-mediated VEGF upregulation under high glucose conditions by PEDF through a mitochondrial ROS pathway in vitro.”Invest Ophthalmol Vis Sci, vol. 51, 2010, pp. 64–71.
[33] Chang, S., et al. “Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development.” Mol Cell Biol, vol. 24, 2004, pp. 8467–76.
[34] Man, J., Barnett, P., and Christoffels, V. M. “Structure and function of the Nppa-Nppbcluster locus during heart development and disease.”Cell, 2018.
[35] Neubauer, S. “The failing heart—an engine out of fuel.” N. Engl. J. Med., 2007.
[36] Cheng, S., Rhee, E. P., Larson, M. G., et al. “Metabolite profiling identifies pathways associated with metabolic risk in humans.” Circulation, vol. 125, 2012, pp. 2222–31.
[37] Sallée, M., Dou, L., Cerini, C., et al. “The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease.”Toxins, vol. 6, 2014, pp. 934–49.
[38] Wang, Y., Liu, H., McKenzie, G., et al. “Kynurenine is an endothelium-derived relaxing factor produced during inflammation.”Nat Med, vol. 16, 2010, pp. 279–85.
[39] Versari, D., Herrmann, J., Gossl, M., Mannheim, D., Sattler, K., Meyer, F. B., et al. “Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis.”Arteriosclerosis, thrombosis, and vascular biol-.
[40] Marfella, R., D’Amico, M., Di Filippo, C., Baldi, A., Siniscalchi, M., Sasso, F. C., et al. “Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment.”Journal.
[41] Dombroski, B. A., Nayak, R. R., Ewens, K. G., Ankener, W., Cheung, V. G., Spielman, S. R. “Gene expression and genetic variation in response to endoplasmic reticulum stress in human cells.” American journal of.
[42] Robert, R., Norez, C., Becq, F. “Disruption of CFTRchloride channel alters mechanical properties and cAMP-dependent Cl- transport of mouse aortic smooth muscle cells.”J Physiol (Lond), vol. 568, 2005, pp. 483-495.
[43] Tousson, A., Van Tine, B. A., Naren, A. P., Shaw, G. M., Schwiebert, L. M. “Characterization of CFTR expression and chloride channel activity in human endothelia.” Am J Physiol Cell Physiol, vol. 275, 1998, pp. C1555-C1564.
[44] Nakano, N., Higashiyama, S., Ohmoto, H., Ishiguro, H., Taniguchi, N., Wada, Y. “The N-terminal region of NTAK/neuregulin-2 isoforms has an inhibitory activity on angiogenesis.” J Biol Chem, vol. 279, 2004, pp. 11465-11470.
[45] Irvin, M. R., et al. “Whole-Exome Sequencing and hiPSC Cardiomyocyte Models Identify MYRIP, TRAPPC11, and SLC27A6of Potential Importance to Left Ventricular Hypertrophy in an African Ancestry Population.”Front Genet, vol. 12, 2021, p. 646927.
[46] Tang, W. H., et al. “Clinical and genetic association of serum ceruloplasmin with cardiovascular risk.”Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 12, 2011, pp. 2955-2962.
[47] Larson, Martin G., et al. “Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes.”BMC Medical Genetics, vol. 8, 2007.
[48] Benjamin, Emelia J., et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Medical Genetics, vol. 8, 2007.